Reuters logo
BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl
September 20, 2017 / 11:16 AM / 3 months ago

BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl

Sept 20 (Reuters) - Eagle Pharmaceuticals Inc

* Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited

* $12.5 million upfront payment plus future potential milestones and royalty payments are part of deal​

* Symbio has estimated that sales of Treakisym are estimated to grow to $90 million in 2018​

* Company will also receive royalties on future net sales of licensed Bendamustine products

* Symbio will target for approval of a product in 2020​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below